Leash Bio’s CTO and co-founder Andrew Blevins reported using Nebius-provided H100s at the Evolved 25 AIxBio Hackathon. His team placed second with research using mutagenesis data to discourage protein-ligand binding models from memorizing proteins.
Leash’s technical account describes training new Hermes models with hackathon compute and mutant protein data. The researchers reported less attention to residues outside conserved protein domains across 20 proteins evaluated. Separately, a Nebius AI Discovery Award announcement named Leash Bio among winners receiving cloud credits and additional support.
Leash Bio reposted Andrew Blevins’s account thanking Nebius for H100s at the Evolved 25 AIxBio Hackathon and describing the team’s second-place protein-ligand model research.
Leash Bio shares Nebius H100 research accountListed 27 Oct 2026 · LinkedIn · Web pageLeash Bio reposted Andrew Blevins’s account thanking Nebius for H100s at the Evolved 25 AIxBio Hackathon and describing the team’s second-place protein-ligand model research.
AI Discovery Award winners receive cloud credits
Published 19 Jun 2025 · LinkedIn · Web page
Artem Elmuratov names Leash Bio among AI Discovery Award winners and states that all winners receive Nebius cloud credits and additional support.
AI Discovery Award winners receive cloud creditsPublished 19 Jun 2025 · LinkedIn · Web pageArtem Elmuratov names Leash Bio among AI Discovery Award winners and states that all winners receive Nebius cloud credits and additional support.
Leash Bio, also known as Leash Biosciences, is a Salt Lake City biotechnology company developing small-molecule medicines with experimental chemistry and machine learning. It screens millions of molecules against protein targets, then uses the resulting interaction data to train models and design new compounds. Its platform combines laboratory screening, a proprietary biochemical dataset and molecule-design software. Leash works with biopharmaceutical partners to identify promising compounds and develops its own therapeutic programs, initially focused on two oncology targets.
Leash Bio releases Minos environments for scientific AI agents
Leash Bio introduced Minos, which lets AI agents explore previously measured protein–molecule experiments and receive immediate experimental feedback. The release includes environments packaged for community evaluation and thousands of agent reasoning traces.
Leash Bio develops medicines using experimental protein-molecule interaction data and machine learning. · Health
How they use Nebius AI Cloud
Leash Bio’s CTO and co-founder Andrew Blevins reported using Nebius-provided H100s at the Evolved 25 AIxBio Hackathon. His team placed second with research using mutagenesis data to discourage protein-ligand binding models from memorizing proteins.
Leash’s technical account describes training new Hermes models with hackathon compute and mutant protein data. The researchers reported less attention to residues outside conserved protein domains across 20 proteins evaluated. Separately, a Nebius AI Discovery Award announcement named Leash Bio among winners receiving cloud credits and additional support.
Leash Bio reposted Andrew Blevins’s account thanking Nebius for H100s at the Evolved 25 AIxBio Hackathon and describing the team’s second-place protein-ligand model research.
Leash Bio shares Nebius H100 research accountListed 27 Oct 2026 · LinkedIn · Web pageLeash Bio reposted Andrew Blevins’s account thanking Nebius for H100s at the Evolved 25 AIxBio Hackathon and describing the team’s second-place protein-ligand model research.
AI Discovery Award winners receive cloud credits
Published 19 Jun 2025 · LinkedIn · Web page
Artem Elmuratov names Leash Bio among AI Discovery Award winners and states that all winners receive Nebius cloud credits and additional support.
AI Discovery Award winners receive cloud creditsPublished 19 Jun 2025 · LinkedIn · Web pageArtem Elmuratov names Leash Bio among AI Discovery Award winners and states that all winners receive Nebius cloud credits and additional support.
Leash Bio, also known as Leash Biosciences, is a Salt Lake City biotechnology company developing small-molecule medicines with experimental chemistry and machine learning. It screens millions of molecules against protein targets, then uses the resulting interaction data to train models and design new compounds. Its platform combines laboratory screening, a proprietary biochemical dataset and molecule-design software. Leash works with biopharmaceutical partners to identify promising compounds and develops its own therapeutic programs, initially focused on two oncology targets.
Leash Bio releases Minos environments for scientific AI agents
Leash Bio introduced Minos, which lets AI agents explore previously measured protein–molecule experiments and receive immediate experimental feedback. The release includes environments packaged for community evaluation and thousands of agent reasoning traces.
